Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Ca
Go back to Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Ca| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 62.25 -0.37 (0.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.62 | 52 Week High | $77.12 | |||
| Open | $62.73 | 52 Week Low | $49.03 | |||
| Day High | $63.08 | P/E | 40.42 | |||
| Day Low | $62.03 | EPS | $1.54 | |||
| Volume | 15,236,954 | |||||
